UBS analyst Joshua Chan lowered the firm’s price target on Exponent (EXPO) to $75 from $85 and keeps a Neutral rating on the shares. The company posted a “solid” quarter with few changes on the 2026 outlook, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXPO:
- Exponent Maintained at Buy as Strong Q1 Beat and Durable Growth Drivers Support Unchanged $66.89 Price Target
- Exponent Earnings Call Highlights Growth And Buybacks
- Exponent Posts Strong Q1 Results, Boosts Capital Returns
- Exponent increases share repurchase authorization by $50M
- Exponent sees FY26 revenues before reimbursements to grow in high-single digits